XCellCure Products

The AMiAware Human Cardiovascular Disease Microarray

Catalog Number AMIKIT001, AMIREF002

IN STOCK

For the simultaneous multiplexed quantitative detection of concentrations of 13 circulating human cardiac biomarkers in plasma.

Novel Multiplex Microarray Using Evidence Based Prognostic and Diagnostic Markers Reporting the Earliest Warning of a Heart Attack and Cardiac Tissue Necrosis


$3600.00 – 50 patient kit for laboratory testing AMIKIT001
$445 – 1 patient send-out testing AMIREF002

 

Cytokines Detected (13) The AMiAware Cardiac Panel Markers - Patents Issued
Format One standard glass slide is spotted with 16 wells of identical antibody arrays. Each antibody is arrayed in quadruplicate. 50 Patients per kit.
Detection Method Fluorescence with laser scanner: Cy3 equivalent dye
Sample Type Heparin Plasma
Sample Volume 50 - 100µL per assay
Species Reactivity Human
Cross-Reactivity There was negligible cross-reactivity between the antibodies for an analyte and all other analytes present on this panel.
Reproducibility CV < 20%
Assay Duration 3 Hours Tech Time

Product Summary

The AMiAware Human Cardiovascular Disease Microarray quantitatively detects 13 Circulating Cardiac Biomarkers, providing rapid and sensitive results in the required clinical range requiring only a single dilution for state-of-the-art prognostic insight on heart tissue damage. This patient-specific Signature of Disease provides critical information on the earliest changes of the coronary vessels that preclude an Acute Myocardial Infarction (AMI) or allow providers to easily monitor cardiac tissue damage after an AMI. This multiplex microarray delivers essential information for understanding processes that lead to heart tissue damage, helps guide treatment to avoid heart tissue damage, and lends critical diagnostic information to inform treatment decisions to improve cardiac function. 

This product may be ordered as a kit for in-house laboratory testing or as a send-out test assayed at the XCellCure, LLC laboratory in St. Louis, MO.

Related Documents: XCellcure Cardiac Biomarker Microarray Brochure

FDA Review Pending. Currently to be utilized as Investigational Use Only.

 


The AMiAware Rapid Cardiac Provider Panel

Catalog Number AMIPOCT001

IN DEVELOPMENT

For the simultaneous multiplexed quantitative detection of concentrations of 13 circulating human cardiac biomarkers in plasma.

Novel Multiplex MicroArray Using Evidence Based Prognostic and Diagnostic Markers Reporting the Earliest Warning of a Heart Attack and Cardiac Tissue Necrosis

Cytokines Detected (13) The AMiAware Cardiac Panel Markers - Patents Issued
Sample Type Human Whole Blood or Heparinized Plasma
Assay Duration 30 minutes

Product Summary

The AMiAware Rapid Cardiac Provider Panel quantitatively detects 13 Circulating Cardiac Biomarkers from a finger prick of blood at the point of care, providing rapid and sensitive results in the required clinical range. This patient-specific Signature of Disease provides critical information on the earliest changes of the coronary vessels that preclude an Acute Myocardial Infarction (AMI) or allows providers to easily monitor cardiac tissue damage after an AMI. This panel provides critical prognostic and diagnostic information to inform treatment decisions to improve cardiac function at the patient bedside. 


The AMiAware Rapid Patient Point of Care Cardiac Panel

Catalog Number AMIPOCT002

IN DEVELOPMENT

For the simultaneous multiplexed quantitative detection of concentrations of 13 circulating human cardiac biomarkers in plasma.

Novel Point of Care Patient Use Cardiac Panel Using Evidence Based Prognostic and Diagnostic Markers to Report the Earliest Warning of a Heart Attack and Cardiac Tissue Necrosis

Cytokines Detected (13) The AMiAware Cardiac Panel Markers - Patents Issued
Sample Type Human Whole Blood
Sample Volume 20µL
Assay Duration 15 minutes

Product Summary

The AMiAware Rapid Patient Point of Care Cardiac Panel detects 13 circulating Cardiac Biomarkers, providing rapid and sensitive results in the required clinical range at the point of care. This patient-specific Signature of Disease provides critical information on the earliest changes of the coronary vessels that preclude an Acute Myocardial Infarction (AMI) and allows patients to send results electronically to a provider of their choice for follow-up, giving patients the option to manage their own cardiac health.